PREVNAR 20 2.2 MCG / 0.5 ML — DIN 02527049
PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 11A : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B : 4.4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 15B : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4 : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6A : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14 : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 33F : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1 : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8 : 2.2 MCG / 0.5 ML CORYNEBACTERIUM DIPHTHERIAE CRM-197 PROTEIN : 51 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 22F : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 10A : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3 : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5 : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 12F : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19F : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 18C : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F : 2.2 MCG / 0.5 ML · PFIZER CANADA ULC · SUSPENSION · wholesale supply in Canada
Health Canada status: MARKETED
What is PREVNAR 20?
PREVNAR 20 2.2 MCG / 0.5 ML contains PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 11A : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B : 4.4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 15B : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4 : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6A : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14 : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 33F : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1 : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8 : 2.2 MCG / 0.5 ML CORYNEBACTERIUM DIPHTHERIAE CRM-197 PROTEIN : 51 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 22F : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 10A : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3 : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5 : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 12F : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19F : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 18C : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F : 2.2 MCG / 0.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02527049, held by PFIZER CANADA ULC, supplied as SUSPENSION for INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 08-Jul-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PREVNAR 20 used for?
PREVNAR 20 is indicated for active immunization of infants, children and adolescents from 6 weeks through 17 years of age (prior to the 18th birthday) for the prevention of invasive pneumococcal disease (including sepsis, meningitis, bacteremic pneumonia, pleural empyema and bacteremia) caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. PREVNAR 20 is also indicated for active immunization of adults 18 years of age and older for the prevention of pneumonia and invasive pneumococcal disease (including sepsis, meningitis, bacteremic pneumonia, pleural empyema and bacteremia) caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Pneumococcus, Purified Polysacc.antigen Conjugated in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
5 holders have a Canadian DIN containing Pneumococcus, Purified Polysacc.antigen Conjugated, across 10 DINs, of which 3 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| MERCK CANADA INC | 4 | 2 | CAPVAXIVE, PNEUMOVAX 23, PNEUMOVAX 23 -(5-DOSE), VAXNEUVANCE | Sourceable in Canada |
| PFIZER CANADA ULC | 3 | 1 | PREVNAR, PREVNAR 13, PREVNAR 20 | Sourceable in Canada |
| GLAXOSMITHKLINE INC | 1 | 0 | SYNFLORIX | No marketed DIN |
| LEDERLE LABS, DIVISION OF AMERICAN CYANAMID CO | 1 | 0 | PNU-IMUNE 23 | No marketed DIN |
| SANOFI PASTEUR LIMITED | 1 | 0 | PNEUMO 23 | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 2.2 MCG / 0.5 ML |
|---|---|
| Dosage form | SUSPENSION |
| Route | INTRAMUSCULAR |
| Pack configuration (monograph) | PREVNAR 20 is supplied in cartons of 1 and 10 single-dose pre-filled syringes, without needles. |
| Storage | Store in a refrigerator between 2°C and 8°C (36°F to 46°F). Syringes should be stored horizontally to minimize re-dispersion time. Do not freeze. Discard if the vaccine has been frozen. Administer as soon as possible after removal from refrigeration. Total cumulative multiple excursions time out of refrigeration (at temperatures between 8°C and 25°C) should not exceed 96 hours. Total time between 0°C and 2°C should not exceed 72 hours (not recommendations for storage). Do not use after the expiry date. |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Substance and classification
| Active substance | Pneumococcus, Purified Polysacc.antigen Conjugated |
|---|---|
| ATC code | J07AL02 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02527049 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2527049 |
| Brand name | PREVNAR 20 |
| Generic / active ingredient | PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 11A : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B : 4.4 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 15B : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4 : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6A : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14 : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 33F : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1 : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8 : 2.2 MCG / 0.5 ML CORYNEBACTERIUM DIPHTHERIAE CRM-197 PROTEIN : 51 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 22F : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 10A : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3 : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5 : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 12F : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19F : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 18C : 2.2 MCG / 0.5 ML PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F : 2.2 MCG / 0.5 ML |
| Market authorization holder | PFIZER CANADA ULC |
| Health Canada schedule | Schedule D |
| ATC code | J07AL02 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J07AL |
| Current status | MARKETED |
| Status date | 08-Jul-2022 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
PREVNAR 20 is administered intramuscularly. Do not mix PREVNAR 20 with any other vaccines or products in the same syringe. Routine Vaccination Schedule for Infants and Toddlers 6 Weeks Through 15 Months of Age (4-Dose Series): 4 doses of 0.5 mL. Primary series: 3 doses, first dose at 2 months (as early as 6 weeks), with 4 to 8 weeks between doses. Fourth dose: between 11 and 15 months of age and at least 2 months after the third dose. Pre-term Infants (<37 Weeks Gestation at Birth): 4 doses of 0.5 mL. Primary series: 3 doses, first dose at 2 months (as early as 6 weeks), with 4 to 8 weeks between doses. Fourth dose: between 11 and 15 months of age and at least 2 months after the third dose. Catch-up Vaccination Schedule for Unvaccinated Children and Adolescents 7 Months Through 17 Years of Age: - Infants 7 Through 11 Months of Age: 3 doses of 0.5 mL, first 2 doses at least 4 weeks apart, third dose after 1-year birthday and at least 2 months after second dose. - Children 12 Through 23 Months of Age: 2 doses of 0.5 mL, with an interval of 2 months between doses. - Children and Adolescents 2 Through 17 Years of Age: One single 0.5 mL dose. Catch-up Vaccination Schedule for Children Previously or Incompletely Vaccinated with PREVNAR 13 (15 months through 17 years of age): 1 single 0.5 mL dose, at least 8 weeks after the final dose of PREVNAR 13. Adults (18 Years of Age and Older): Single 0.5 mL dose intramuscularly. Administration: Hold pre-filled syringe horizontally and shake vigorously until homogeneous white suspension. Visually inspect for particulate matter or discoloration. Remove syringe cap by turning counter-clockwise. Attach sterile needle appropriate for intramuscular administration by turning clockwise. Inject intramuscularly into anterolateral aspect of thigh (infants) or deltoid muscle of upper arm (children and adults). Do not administer intravascularly.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
PREVNAR 20 is contraindicated in individuals who are hypersensitive to the active substance or to any component of the vaccine, including diphtheria toxoid.
Warnings and precautions
As with all injectable vaccines, appropriate medical treatment and supervision must always be readily available in case of a rare anaphylactic event following the administration of the vaccine. Administration should be postponed in individuals suffering from acute severe febrile illness. Minor infection (e.g., cold) should not defer vaccination. PREVNAR 20 only protects against Streptococcus pneumoniae serotypes included in the vaccine and may not protect all individuals. The potential risk of apnea should be considered when administering the primary immunization series to preterm infants (born ≤28 weeks of gestation) who remain hospitalized; monitoring for at least 48 hours after vaccination should be considered. Vaccination should not be withheld or delayed in this group due to high benefit.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
3 of 10 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| CAPVAXIVE | 4 MCG / 0.5 ML | SOLUTION | MERCK CANADA INC | MARKETED | 02549891 |
| VAXNEUVANCE | 30 MCG / 0.5 ML | SUSPENSION | MERCK CANADA INC | MARKETED | 02522403 |
| PNEUMO 23 | 25 MCG / 0.5 ML | LIQUID | SANOFI PASTEUR LIMITED | CANCELLED POST MARKET | 02231259 |
| PNEUMOVAX 23 | 25 MCG / 0.5 ML | SOLUTION | MERCK CANADA INC | CANCELLED POST MARKET | 00431648 |
| PNEUMOVAX 23 -(5-DOSE) | 25 MCG / 0.5 ML | SOLUTION | MERCK CANADA INC | CANCELLED POST MARKET | 02240632 |
| PNU-IMUNE 23 | 25 MCG / 0.5 ML | LIQUID | LEDERLE LABS, DIVISION OF AMERICAN CYANAMID CO | CANCELLED POST MARKET | 02230175 |
| PREVNAR | 20 MCG / 0.5 ML | SUSPENSION | PFIZER CANADA ULC | CANCELLED POST MARKET | 02244081 |
| PREVNAR 13 | 2.2 MCG / 0.5 ML | SUSPENSION | PFIZER CANADA ULC | CANCELLED POST MARKET | 02335204 |
| SYNFLORIX | 3 MCG / 0.5 ML | SUSPENSION | GLAXOSMITHKLINE INC | CANCELLED POST MARKET | 02320541 |
2 · Same class — other molecules in ATC J07AL
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Pneumococcus, Purified Polysacc.antigen Conjugated | CAPVAXIVE · PNEUMO 23 · PNEUMOVAX 23 · PNEUMOVAX 23 -(5-DOSE) · +6 more | 10 | 3 | Yes |
| Pneumococcus, Purified Polysaccharides Antigen | PNEUMOVAX 23 | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J07A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J07AH | Meningococcal Vaccines · Meningococcus B, Multicomponent Vaccine · Meningococcus C, Purified Polysaccharides Antigen Conjugated · Meningococcus, A, C, Bivalent Purified Polysacc. Antigen · Meningococcus, A, C, Y, W-135, Tetraval. Purified Polysacc. Antigen · +1 more | 17 | 6 |
| J07AE | Cholera, Inactivated, Whole Cell · Cholera, Live Attenuated | 4 | 2 |
| J07AP | Typhoid, Inactivated, Whole Cell · Typhoid, Oral, Live Attenuated · Typhoid, Purified Polysaccharide Antigen | 5 | 2 |
| J07AM | Tetanus Toxoid · Tetanus Toxoid, Comb. With Diphtheria Toxoid | 7 | 1 |
| J07AX | Other Bacterial Vaccines | 4 | 1 |
| J07AG | Hemophilus Influenzae B Vaccines · Hemophilus Influenzae B, Combinations With Pertussis And Toxoids · Hemophilus Influenzae B, Combinations With Toxoids · Hemophilus Influenzae B, Purified Antig. Conjugated | 8 | 1 |
| J07AJ | Pertussis, Inact., Whole Cell, Comb. With Toxoids · Pertussis, Inactivated, Whole Cell · Pertussis, Purified Antigen · Pertussis, Purified Antigen, Comb. With Toxoids | 7 | 1 |
| J07AN | Tuberculosis, Live Attenuated | 2 | 0 |
4 · Fixed-dose combinations with Canadian supply
| Product | Active ingredients | Holder | Status | DIN |
|---|---|---|---|---|
| ADACEL | PERTUSSIS TOXOID : 2.5 MCG / 0.5 ML FILAMENTOUS HAEMAGGLUTININ : 5 MCG / 0.5 ML DIPHTHERIA TOXOID : 2 LF / 0.5 ML PERTACTIN : 3 MCG / 0.5 ML FIMBRIAE TYPES 2 AND 3 (FIM) : 5 MCG / 0.5 ML TETANUS TOXOID : 5 LF / 0.5 ML | SANOFI PASTEUR LIMITED | MARKETED | 02240255 |
| DUKORAL | VIBRIO CHOLERAE INABA 48 CLASSICAL BIOTYPE, HEAT INACTIVATED : 31250000000 CELLS VIBRIO CHOLERAE OGAWA 50 CLASSICAL BIOTYPE, FORMALIN INACTIVATED : 31250000000 CELLS VIBRIO CHOLERAE INABA 6973 EL TOR BIOTYPE, FORMALIN INACTIVATED : 31250000000 CELLS VIBRIO CHOLERAE OGAWA 50 CLASSICAL BIOTYPE, HEAT INACTIVATED : 31250000000 CELLS RECOMBINANT CHOLERA TOXIN B SUBUNIT : 1 MG | VALNEVA SWEDEN AB | MARKETED | 02247208 |
| VAXCHORA | VIBRIO CHOLERAE, STRAIN CVD 103-HGR, LIVE : 2000000000 UNIT | BAVARIAN NORDIC AS | MARKETED | 02538164 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is PREVNAR 20 called?
Also recorded in Canada as: APEVEXX (EU), APEVEXX (UK), PREVENAR 20 (GLOBAL), Pneumococcal 20-valent Conjugate Vaccine (GLOBAL).
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.